Menu
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted today to recommend the use of variant-specific boosters. Out of 21 voting members, 19 supported the use of a SARS-CoV-2 omicron component for COVID-19 booster vaccines. “I want to be clear that this doesn’t mean that we are saying that there will be boosters recommended for everyone…
3D Systems and EMS-GRILTECH announced they have entered into a strategic partnership to enhance additive manufacturing materials development. Combining 3D Systems’ expertise and leadership as an additive manufacturing solutions partner with EMS-GRILTECH’s (a Business Unit of EMS Group) expertise in the specialized manufacturing of polyamides has enabled the companies to introduce a novel nylon copolymer […]
Last month, nearly 900 attendees gathered for NAHAD’s 38th Annual Meeting and Convention at the Fontainebleau Miami Beach to reconnect with existing clients, engage with new customers, and take part in multiple educational sessions. The convention ran from May 15-18, and was kicked off with the “State of NAHAD” report by 2021-2022 by President Jeff […]
FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted today to recommend the use of variant-specific boosters. Out of 21 voting members, 19 supported the use of a SARS-CoV-2 omicron component for COVID-19 booster vaccines. “I want to be clear that this doesn’t mean that we are saying that there will be boosters recommended for everyone…
Last month, nearly 900 attendees gathered for NAHAD’s 38th Annual Meeting and Convention at the Fontainebleau Miami Beach to reconnect with existing clients, engage with new customers, and take part in multiple educational sessions. The convention ran from May 15-18, and was kicked off with the “State of NAHAD” report by 2021-2022 by President Jeff […]
AtriCure Inc. (NASDAQ:ATRC) shares, rose in value on Friday, 06/24/22, with the stock price up by 3.75% to the previous day’s close as strong demand from buyers drove the stock to $40.92. Actively observing the price movement in the last trading, the stock closed the session at $39.44, falling within a range of $39.08 and … AtriCure Inc. (NASDAQ: ATRC) Stock Could Be An Option To Consider Read More »
3Spine announced today that it received FDA investigational device exemption (IDE) for its Motus spinal implant device. Chattanooga, Tennessee-based 3Spine designed the Motus device for use in the BalancedBack total joint replacement procedure. 3Spine’s BalancedBack procedure is indicated for the biomechanical reconstruction and stabilization of a spinal motion segment following decompression at one lumbar level […]
AtriCure presents with numerous inflection points that sit on the distant horizon. Hence, we rate ATRC stock neutral. Click here to see why.
Analysts expect AtriCure, Inc. to report earnings per share of for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for…
AtriCure Inc. (NASDAQ:ATRC)’s traded shares stood at 0.32 million during the last session, with the company’s beta value hitting 1.17. At the close of trading, the stock’s price was $44.98, to imply a decrease of -9.15% or -$4.53 in intraday trading. The ATRC share’s 52-week high remains $89.18, putting it -98.27% down since that peak … AtriCure Inc. (NASDAQ: ATRC) Stock Dropped -27.50% Over A Month – Any Room To Run? Read More »